ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Renin-Angiotensin-System (RAS)-Acting Agent Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-5Q14323
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Renin Angiotensin System RAS Acting Agent Market Research Report 2023
BUY CHAPTERS

Global Renin-Angiotensin-System (RAS)-Acting Agent Market Research Report 2025

Code: QYRE-Auto-5Q14323
Report
May 2025
Pages:79
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Pfizer Inc
Astrazeneca plc
Merck& Co. Inc
Sanofi
Bristol Myers Squibb Company
Daiichi Sankyo Company Limited
Takeda Pharmaceutical Company Limited
Johnson & Johnson
Boehringer lngelheim GmbH

Renin-Angiotensin-System (RAS)-Acting Agent Market Size

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years.

Renin-Angiotensin-System (RAS)-Acting Agent Market

Renin-Angiotensin-System (RAS)-Acting Agent Market

The global market for Renin-Angiotensin-System (RAS)-Acting Agent was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Renin-Angiotensin-System (RAS)-Acting Agent, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Renin-Angiotensin-System (RAS)-Acting Agent.
The Renin-Angiotensin-System (RAS)-Acting Agent market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Renin-Angiotensin-System (RAS)-Acting Agent market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Renin-Angiotensin-System (RAS)-Acting Agent manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Renin-Angiotensin-System (RAS)-Acting Agent Market Report

Report Metric Details
Report Name Renin-Angiotensin-System (RAS)-Acting Agent Market
Accounted market size in year US$ 603 billion
CAGR 5%
Base Year year
Segment by Type
  • Angiotensin Converting Enzyme Inhibitors (ACEi)
  • Angiotensin Receptor Blockers (ARBs)
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company,Limited, Takeda Pharmaceutical Company Limited, Boehringer lngelheim GmbH, Johnson & Johnson
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Renin-Angiotensin-System (RAS)-Acting Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Renin-Angiotensin-System (RAS)-Acting Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Renin-Angiotensin-System (RAS)-Acting Agent Market report?

Ans: The main players in the Renin-Angiotensin-System (RAS)-Acting Agent Market are Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company,Limited, Takeda Pharmaceutical Company Limited, Boehringer lngelheim GmbH, Johnson & Johnson

What are the Application segmentation covered in the Renin-Angiotensin-System (RAS)-Acting Agent Market report?

Ans: The Applications covered in the Renin-Angiotensin-System (RAS)-Acting Agent Market report are Hypertension, Heart Failure, Chronic Kidney Disease, Other

What are the Type segmentation covered in the Renin-Angiotensin-System (RAS)-Acting Agent Market report?

Ans: The Types covered in the Renin-Angiotensin-System (RAS)-Acting Agent Market report are Angiotensin Converting Enzyme Inhibitors (ACEi), Angiotensin Receptor Blockers (ARBs)

Recommended Reports

Cardiovascular Devices

Imaging Systems

Pharmaceutical Actives

1 Renin-Angiotensin-System (RAS)-Acting Agent Market Overview
1.1 Product Definition
1.2 Renin-Angiotensin-System (RAS)-Acting Agent by Type
1.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Value Comparison by Type (2024 VS 2031)
1.2.2 Angiotensin Converting Enzyme Inhibitors (ACEi)
1.2.3 Angiotensin Receptor Blockers (ARBs)
1.3 Renin-Angiotensin-System (RAS)-Acting Agent by Application
1.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Value by Application (2024 VS 2031)
1.3.2 Hypertension
1.3.3 Heart Failure
1.3.4 Chronic Kidney Disease
1.3.5 Other
1.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Estimates and Forecasts
1.4.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue 2020-2031
1.4.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales 2020-2031
1.4.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Renin-Angiotensin-System (RAS)-Acting Agent Market Competition by Manufacturers
2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Manufacturers (2020-2025)
2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Renin-Angiotensin-System (RAS)-Acting Agent, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, Product Type & Application
2.7 Global Key Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, Date of Enter into This Industry
2.8 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Competitive Situation and Trends
2.8.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Renin-Angiotensin-System (RAS)-Acting Agent Players Market Share by Revenue
2.8.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Scenario by Region
3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2020-2031
3.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2020-2025
3.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2026-2031
3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region: 2020-2031
3.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region: 2020-2025
3.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region: 2026-2031
3.4 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Country
3.4.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2031)
3.4.3 North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Country
3.5.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2031)
3.5.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Region
3.6.1 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2020-2031)
3.6.3 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Country
3.7.1 Latin America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2031)
3.7.3 Latin America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Country
3.8.1 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2031)
3.8.3 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2020-2031)
4.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2020-2025)
4.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2026-2031)
4.1.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2020-2031)
4.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2020-2031)
4.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2020-2025)
4.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2026-2031)
4.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2020-2031)
4.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2020-2031)
5 Segment by Application
5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2020-2031)
5.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2020-2025)
5.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2026-2031)
5.1.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2020-2031)
5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2020-2031)
5.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2020-2025)
5.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2026-2031)
5.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2020-2031)
5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novartis AG
6.1.1 Novartis AG Company Information
6.1.2 Novartis AG Description and Business Overview
6.1.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.1.5 Novartis AG Recent Developments/Updates
6.2 Pfizer, Inc.
6.2.1 Pfizer, Inc. Company Information
6.2.2 Pfizer, Inc. Description and Business Overview
6.2.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.2.5 Pfizer, Inc. Recent Developments/Updates
6.3 AstraZeneca plc
6.3.1 AstraZeneca plc Company Information
6.3.2 AstraZeneca plc Description and Business Overview
6.3.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.3.5 AstraZeneca plc Recent Developments/Updates
6.4 Merck & Co., Inc.
6.4.1 Merck & Co., Inc. Company Information
6.4.2 Merck & Co., Inc. Description and Business Overview
6.4.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.4.5 Merck & Co., Inc. Recent Developments/Updates
6.5 Sanofi S.A.
6.5.1 Sanofi S.A. Company Information
6.5.2 Sanofi S.A. Description and Business Overview
6.5.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.5.5 Sanofi S.A. Recent Developments/Updates
6.6 Bristol-Myers Squibb Company
6.6.1 Bristol-Myers Squibb Company Company Information
6.6.2 Bristol-Myers Squibb Company Description and Business Overview
6.6.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.6.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.7 Daiichi Sankyo Company,Limited
6.7.1 Daiichi Sankyo Company,Limited Company Information
6.7.2 Daiichi Sankyo Company,Limited Description and Business Overview
6.7.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.7.5 Daiichi Sankyo Company,Limited Recent Developments/Updates
6.8 Takeda Pharmaceutical Company Limited
6.8.1 Takeda Pharmaceutical Company Limited Company Information
6.8.2 Takeda Pharmaceutical Company Limited Description and Business Overview
6.8.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.8.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
6.9 Boehringer lngelheim GmbH
6.9.1 Boehringer lngelheim GmbH Company Information
6.9.2 Boehringer lngelheim GmbH Description and Business Overview
6.9.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.9.5 Boehringer lngelheim GmbH Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Company Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Renin-Angiotensin-System (RAS)-Acting Agent Industry Chain Analysis
7.2 Renin-Angiotensin-System (RAS)-Acting Agent Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Renin-Angiotensin-System (RAS)-Acting Agent Production Mode & Process Analysis
7.4 Renin-Angiotensin-System (RAS)-Acting Agent Sales and Marketing
7.4.1 Renin-Angiotensin-System (RAS)-Acting Agent Sales Channels
7.4.2 Renin-Angiotensin-System (RAS)-Acting Agent Distributors
7.5 Renin-Angiotensin-System (RAS)-Acting Agent Customer Analysis
8 Renin-Angiotensin-System (RAS)-Acting Agent Market Dynamics
8.1 Renin-Angiotensin-System (RAS)-Acting Agent Industry Trends
8.2 Renin-Angiotensin-System (RAS)-Acting Agent Market Drivers
8.3 Renin-Angiotensin-System (RAS)-Acting Agent Market Challenges
8.4 Renin-Angiotensin-System (RAS)-Acting Agent Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novartis
Pfizer Inc
Astrazeneca plc
Merck& Co. Inc
Sanofi
Bristol Myers Squibb Company
Daiichi Sankyo Company Limited
Takeda Pharmaceutical Company Limited
Johnson & Johnson
Boehringer lngelheim GmbH
List of Tables
 Table 1. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Renin-Angiotensin-System (RAS)-Acting Agent Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Renin-Angiotensin-System (RAS)-Acting Agent, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, Product Type & Application
 Table 12. Global Key Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Renin-Angiotensin-System (RAS)-Acting Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Renin-Angiotensin-System (RAS)-Acting Agent as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2020-2025) & (K Units)
 Table 18. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2020-2025)
 Table 19. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2026-2031) & (K Units)
 Table 20. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2026-2031)
 Table 21. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2020-2025)
 Table 23. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2026-2031)
 Table 25. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2025) & (K Units)
 Table 27. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2026-2031) & (K Units)
 Table 28. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units) by Type (2020-2025)
 Table 51. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units) by Type (2026-2031)
 Table 52. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2020-2025)
 Table 53. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2026-2031)
 Table 54. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2020-2025)
 Table 57. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2026-2031)
 Table 58. Global Renin-Angiotensin-System (RAS)-Acting Agent Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Renin-Angiotensin-System (RAS)-Acting Agent Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units) by Application (2020-2025)
 Table 61. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units) by Application (2026-2031)
 Table 62. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2020-2025)
 Table 63. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2026-2031)
 Table 64. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2020-2025)
 Table 67. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2026-2031)
 Table 68. Global Renin-Angiotensin-System (RAS)-Acting Agent Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Renin-Angiotensin-System (RAS)-Acting Agent Price (US$/Unit) by Application (2026-2031)
 Table 70. Novartis AG Company Information
 Table 71. Novartis AG Description and Business Overview
 Table 72. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 74. Novartis AG Recent Developments/Updates
 Table 75. Pfizer, Inc. Company Information
 Table 76. Pfizer, Inc. Description and Business Overview
 Table 77. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 79. Pfizer, Inc. Recent Developments/Updates
 Table 80. AstraZeneca plc Company Information
 Table 81. AstraZeneca plc Description and Business Overview
 Table 82. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 84. AstraZeneca plc Recent Developments/Updates
 Table 85. Merck & Co., Inc. Company Information
 Table 86. Merck & Co., Inc. Description and Business Overview
 Table 87. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 89. Merck & Co., Inc. Recent Developments/Updates
 Table 90. Sanofi S.A. Company Information
 Table 91. Sanofi S.A. Description and Business Overview
 Table 92. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 94. Sanofi S.A. Recent Developments/Updates
 Table 95. Bristol-Myers Squibb Company Company Information
 Table 96. Bristol-Myers Squibb Company Description and Business Overview
 Table 97. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 99. Bristol-Myers Squibb Company Recent Developments/Updates
 Table 100. Daiichi Sankyo Company,Limited Company Information
 Table 101. Daiichi Sankyo Company,Limited Description and Business Overview
 Table 102. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 104. Daiichi Sankyo Company,Limited Recent Developments/Updates
 Table 105. Takeda Pharmaceutical Company Limited Company Information
 Table 106. Takeda Pharmaceutical Company Limited Description and Business Overview
 Table 107. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 109. Takeda Pharmaceutical Company Limited Recent Developments/Updates
 Table 110. Boehringer lngelheim GmbH Company Information
 Table 111. Boehringer lngelheim GmbH Description and Business Overview
 Table 112. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 114. Boehringer lngelheim GmbH Recent Developments/Updates
 Table 115. Johnson & Johnson Company Information
 Table 116. Johnson & Johnson Description and Business Overview
 Table 117. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product
 Table 119. Johnson & Johnson Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Renin-Angiotensin-System (RAS)-Acting Agent Distributors List
 Table 123. Renin-Angiotensin-System (RAS)-Acting Agent Customers List
 Table 124. Renin-Angiotensin-System (RAS)-Acting Agent Market Trends
 Table 125. Renin-Angiotensin-System (RAS)-Acting Agent Market Drivers
 Table 126. Renin-Angiotensin-System (RAS)-Acting Agent Market Challenges
 Table 127. Renin-Angiotensin-System (RAS)-Acting Agent Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Renin-Angiotensin-System (RAS)-Acting Agent
 Figure 2. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Share by Type: 2024 & 2031
 Figure 4. Angiotensin Converting Enzyme Inhibitors (ACEi) Product Picture
 Figure 5. Angiotensin Receptor Blockers (ARBs) Product Picture
 Figure 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Share by Application: 2024 & 2031
 Figure 8. Hypertension
 Figure 9. Heart Failure
 Figure 10. Chronic Kidney Disease
 Figure 11. Other
 Figure 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (2020-2031) & (K Units)
 Figure 15. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price (US$/Unit) & (2020-2031)
 Figure 16. Renin-Angiotensin-System (RAS)-Acting Agent Report Years Considered
 Figure 17. Renin-Angiotensin-System (RAS)-Acting Agent Sales Share by Manufacturers in 2024
 Figure 18. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Renin-Angiotensin-System (RAS)-Acting Agent Players: Market Share by Revenue in Renin-Angiotensin-System (RAS)-Acting Agent in 2024
 Figure 20. Renin-Angiotensin-System (RAS)-Acting Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2020-2031)
 Figure 23. North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country (2020-2031)
 Figure 24. United States Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2020-2031)
 Figure 27. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2020-2031)
 Figure 35. China Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. China Taiwan Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Latin America Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2020-2031)
 Figure 43. Latin America Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country (2020-2031)
 Figure 44. Mexico Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Brazil Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Argentina Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of Renin-Angiotensin-System (RAS)-Acting Agent by Type (2020-2031)
 Figure 53. Global Revenue Market Share of Renin-Angiotensin-System (RAS)-Acting Agent by Type (2020-2031)
 Figure 54. Global Renin-Angiotensin-System (RAS)-Acting Agent Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of Renin-Angiotensin-System (RAS)-Acting Agent by Application (2020-2031)
 Figure 56. Global Revenue Market Share of Renin-Angiotensin-System (RAS)-Acting Agent by Application (2020-2031)
 Figure 57. Global Renin-Angiotensin-System (RAS)-Acting Agent Price (US$/Unit) by Application (2020-2031)
 Figure 58. Renin-Angiotensin-System (RAS)-Acting Agent Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

RAS acting Agents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Angiotensin II Receptor Market Research Report 2024
Global Non Peptide Drugs of Angiotensin II Receptor Antagonist Market Research Report 2024
Angiotensin Receptor Antagonists Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Renin Angiotensin System RAS Inhibitor Market Research Report 2024
Angiotensin Converting Enzyme Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Angiotensin Receptor Blockers ARBs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cardiovascular Intervention Robot Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Angiotensin Converting Enzyme ACE Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Angiotensin II Receptor Blocker ARBs API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antiangiogenic Agent Market Research Report 2025
Computer Assisted Surgical CAS Solution Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
PAPR Respirator System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Health and Medical Reinsurance Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Surgical Planning and Evaluation System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hospital Real time Location Systems Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Angiography Imaging Systems Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Healthcare Revenue Cycle Management RCM Software Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Medical Flow Restrictor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Angiotensin II Receptor Blockers Market Insights Forecast to 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions